Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 27Neoplasms 9Neoplasm Metastasis 9Breast Neoplasms 9Kidney Neoplasms 6Prostatic Neoplasms 4Gastrointestinal Stromal Tumors 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms by Histologic Type 3Melanoma 3Liver Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Primary Myelofibrosis 2Neuroendocrine Tumors 2Neoplasms, Glandular and Epithelial 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Digestive System Neoplasms 2Clear-cell metastatic renal cell carcinoma 2

Interventions

Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urogenital Diseases × Sunitinib × Clear all
NCT00912912 2016-04-15

Sunitinib Malate in Refractory Germ Cell Tumors

M.D. Anderson Cancer Center

Phase 2 Terminated
5 enrolled 6 charts

Urogenital Diseases, Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡